The 40th JPM 2022 Healthcare Conference se celebró from January 10th to 13th, with digital meetings continuing until the end of January, enabling exchanges among empresas farmacéuticas from around the world.
This meeting brought together a large number of nacional pharmaceutical and bio empresas, including Samsung Biologics, making it an occasion to discuss global transferencia de tecnologías.
With many nacional empresas participating in the main track, emerging track, and Asia-Pacific sessions, RudaCure was also able to continue discussions on RCI001 and RCI002 with interested parties including Kintor, Qilu, Alimera Sciences, and AbbVie through this JPM conferencia.
Among these, AbbVie expresó significant interest in RCI001, showing great enthusiasm for the ensayo clínico progreso and expressing amazement at the drug's eficacia through its novel mecanismo de acción, hoping to establish an ongoing relationship. Chinese empresas were also able to exchange information about mercado conditions in China.